New York, NY, Sept. 11, 2026 (GLOBE NEWSWIRE) -- In a monitoring inquiry, BBB National Programs’ National Advertising Division recommended that Nucleus Genomics, Inc. modify or discontinue certain express and implied advertising claims for its Nucleus IVF+ service, including claims that Nucleus IVF+ could accurately compare embryos' disease risks, identify which embryo would grow up tallest or smartest, and determine a future child’s eye and hair colors. Nucleus will appeal the National Advertising Division’s (NAD) decision.